Zoledronic acid (Zometa)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:16, 3 October 2015 by Jwarner (talk | contribs)
Jump to navigation Jump to search

General information

Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis, and inhibits skeletal calcium release by tumor stimulatory factors.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Dosing

  • CALGB 70604 results, published as abstract only, demonstrate non-inferiority of 3-month dosing vs. monthly dosing.[4]

Patient drug information

Also known as

Acido Zoledronico, Aclasta, Blaztere, Cytozol, Reclast, Servycal, Tianqing YI TAI, Zhuo LAI, Zobone, Zoldonat, Zoledronate, Zoledronate Disodium, Zoledronic Acid, Zomera, Zometa, Zyfoss

References

  1. 1.0 1.1 1.2 Zoledronic acid (Zometa) package insert
  2. Zoledronic acid (Zometa) package insert (locally hosted backup)
  3. Zometa manufacturer's site
  4. Himelstein, Andrew Louis, Qin, Rui, Novotny, Paul J., Seisler, Drew K., Khatcheressian, James L., Roberts, John D., Grubbs, Stephen S., O'Connor, Tracey, Weckstein, Douglas, Loprinzi, Charles L., Shapiro, Charles L. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol (Meeting Abstracts) 2015 33: 9501 link to abstract
  5. Zoledronic acid (Zometa) patient drug information (Chemocare)
  6. Zoledronic acid (Zometa) patient drug information (UpToDate)